Benzinga's Top #PreMarket Losers By: Benzinga via Benzinga April 04, 2014 at 08:22 AM EDT Halozyme Therapeutics (NASDAQ: HALO) fell 23.73% to $8.84 in pre-market trading after the company announced the temporary halt of Phase ... Read More >> Related Stocks: CarMax Halozyme Therapeutic